Awarded the First Domestic Class II Certificate for "Blood Glucose Data Analysis," Zhongqi Huakang Accelerates Precision Management for Diabetes!

Recently, "Ai Tang - Blood Glucose Data Analysis Software" (hereinafter referred to as Ai Tang), independently developed by Beijing Zhongqi Huakang Technology Development Co., Ltd. (hereinafter referred to as Zhongqi Huakang), has been officially approved. It has become the first standalone blood glucose analysis software in China to obtain a Class II medical device registration certificate for "blood glucose data analysis." This marks a further step towards digitalization and precision in diabetes management in China.

Founded in 2012, based on the founder's background in biomaterials from Tsinghua University, nearly 20 years of deep experience in the medical device industry, 8 years of market experience in international renowned enterprises, and a multidisciplinary team with expertise in medicine, artificial intelligence, device R&D, marketing, and other fields, ZQHK has built five major business platforms: a specialized disease management system, decision support system, intelligent follow-up system, disease tracking system, and clinical research system. These form a comprehensive data-driven digital therapy solution for diabetes, enabling real-time monitoring, data analysis, intelligent evaluation, and remote healthcare management of various vital signs or critical parameters. To date, ZQHK has served over 800 hospitals and more than 120,000 users domestically.

Based on its profound accumulation in the medical field, Zhongqi Huakang has developed "Ai Tang - Blood Glucose Data Analysis Software," which helps breakthrough the "dimension wall" between in-hospital and out-of-hospital diabetes management, achieving precise management in all scenarios.

The management of diabetes in our country is not optimistic and faces enormous challenges.

According to the "Diabetes Market Trend Insights Report" by Sino Health Technology, in 2024, the number of people with diabetes in China has reached 148 million, the highest in the world. However, in stark contrast to the large number of patients is the extremely low control rate, which is only 16.5%. Additionally, the awareness and treatment rates among Chinese diabetes patients are also relatively low, at 36.7% and 32.9%, respectively. This means that more than half of the patients in China remain undiagnosed or are not effectively managed.

The reasons for this phenomenon are not only the lack of awareness and insufficient early screening for diabetes, but also related to the absence of refined management mechanisms. The lack of such mechanisms is associated with factors like a shortage of medical professionals, the absence of refined management tools, and difficulties in breaking down data silos.

In response, a group of enterprises have actively invested in this area, dedicating themselves to providing refined management tools for patients and medical institutions. They even offer a comprehensive diabetes management closed-loop solution that covers all scenarios both inside and outside the hospital, from monitoring and analysis to intervention.

Zhongqi Huakang is one of them. Zhongqi Huakang's "Ai Tang - Blood Glucose Data Analysis Software" is the latest achievement in its efforts to cultivate the field of digital and refined management of diabetes.

As an independent software, Zhongqi Huakang's "Ai Tang - Blood Glucose Data Analysis Software" can support mainstream brands of continuous glucose monitoring devices in the domestic market, offering more choices for hospitals, researchers, and patients. By collecting dynamic glucose data from compatible devices, the software enables multi-modal and multi-dimensional analysis of glucose data.

This is mainly due to the company's self-developed blood glucose data algorithms and models. According to Zhongqi Huakang, it has uniquely created the Hexagon Model and the Propeller Model. The Hexagon Model includes six key indicators: TIR, TOR, Intensity HYPER (hyperglycemia intensity), Intensity HYPO (hypoglycemia intensity), LAGE (maximum glucose fluctuation), and GRADE (glucose risk), providing an intuitive display of core blood glucose control metrics and identifying breakthrough points for blood glucose management. The Propeller Model incorporates 11 extended indicators, assisting in uncovering user risk warnings while also supporting clinical research.

Compared with the pentagon model commonly used in the industry, Zhongqi Huakang's hexagon model can analyze blood glucose data in more dimensions with greater precision. It can also integrate patients' blood glucose monitoring data, dietary records, exercise information, and medication usage in real time based on big data analysis technology. Through a comprehensive health algorithm, it automatically generates personalized blood glucose trend reports.

It is reported that the software is mainly targeted at people with type 1 diabetes, type 2 diabetes, impaired glucose tolerance, insulin-treated individuals, gestational diabetes patients, critically ill blood glucose management patients, perioperative blood glucose management patients, and chronic disease populations such as obesity.

Notably, the software includes a blood glucose collection client, a patient management client, and a central blood glucose monitoring and management workstation. It is compatible with data collection, intelligent data analysis, patient management, and device management function modules. This enables it to not only achieve blood glucose management across multiple departments in the hospital but also realize precise and digital blood glucose management both inside and outside the hospital.

Not only that, but the "intelligent early warning system" equipped in this software can also accurately identify the risk of abnormal blood glucose fluctuations, transforming passive treatment into active prevention.

The R&D director of Zhongqi Huakang said, "The core value of 'Ai Tang - Blood Glucose Data Analysis Software' lies in transforming 'digital therapeutics' from a concept into an accessible medical tool. By building a closed-loop system of 'monitoring - analysis - intervention,' we enable every diabetes patient to have their own dedicated 'blood glucose management advisor,' freeing healthcare professionals from cumbersome data organization and allowing them to focus on developing precise treatment plans."

The founding team of Zhongqi Huakang stated, "The approval of 'Ai Tang - Blood Glucose Data Analysis Software' is not only a milestone for Zhongqi Huakang in the field of digital healthcare but also an accelerator in advancing diabetes management in China towards intelligence, standardization, and personalization."

It is reported that "Ai Tang - Blood Glucose Data Analysis Software" has been successfully implemented and productized. The next step for Zhongqi Huakang is to collaborate with commercial partners to introduce a diabetes chronic disease management solution, integrated with the "Ai Tang - Blood Glucose Data Analysis Software," to hospitals, rehabilitation centers, smart communities, and internet hospitals, among other institutions/scenarios.

In the future, with the continuous iteration of technology, Zhongqi Huakang is expected to further integrate intelligent medical wearable devices, build a specialized disease knowledge graph database based on multimodal data modeling, and provide diabetes patients with full-cycle, multi-dimensional health management solutions, supporting the in-depth advancement of the "Healthy China" strategy in the field of chronic disease prevention and treatment.